Stem Cells Linked to Functional Recovery of Heart Post MILast Updated: March 18, 2011. In patients with left ventricular dysfunction due to remote myocardial infarction, injections of autologous bone marrow progenitor cells reduce heart size and scar tissue size, and improve regional contractility, according to a study published online March 17 in Circulation Research.
FRIDAY, March 18 (HealthDay News) -- In patients with left ventricular (LV) dysfunction due to remote myocardial infarction, injections of autologous bone marrow progenitor cells reduce heart size and scar tissue size, and improve regional contractility, according to a study published online March 17 in Circulation Research.
Adam R. Williams, M.D., from the Interdisciplinary Stem Cell Institute in Miami, and colleagues assessed functional recovery and reverse remodeling of scarred myocardium in eight patients with ischemic cardiomyopathy. Autologous bone marrow progenitor cells (mononuclear or mesenchymal stem cells) were injected into the LV scar and border zone. Cardiac magnetic resonance imaging (CMR) was used to assess the structure and function of scarred myocardium at baseline, at three and six months, and one year after cell therapy.
The investigators found that the procedure was tolerated by all patients without any serious adverse events. At three months, there was improvement in regional LV function, and the changes in chamber dimensions were significant at six months. At one year, CMR showed a decrease in end-diastolic volume (EDV) and infarct size, and a trend toward decreased end-systolic volume (ESV). Eulerian circumferential strain at one year showed improved regional LV function, which was strongly associated with the reduction of EDV and ESV.
"Our data suggest human autologous bone marrow progenitor cells increase regional contractility of injected myocardial scar tissue within three months of treatment, and these functional changes are associated with later reverse remodeling," the authors write.
Several of the study authors are employees of BioCardia Inc., which partially funded the study.
|Previous: Bulking Agent Injections Effective in Fecal Incontinence||Next: Daily Hemodialysis Helps Restless Legs Syndrome|
Reader comments on this article are listed below. Review our comments policy.